Notice of Award of a Sole Source Cooperative Agreement To Fund the Pan-American Health Organization (PAHO), 8433-8434 [2024-02507]

Download as PDF khammond on DSKJM1Z7X2PROD with NOTICES Federal Register / Vol. 89, No. 26 / Wednesday, February 7, 2024 / Notices laboratories in Rwanda, and establishes relations and collaborations with other national and international agencies carrying out similar responsibilities. No other agency in the public or private sector performs this responsibility. South African Medical Research Council is in a unique position to conduct this work, as it is a government body responsible for biomedical research of national importance and is the only agency with this direct governmental mandate in South Africa. SANAC is in a unique position to conduct this work, as it is mandated to coordinate a truly multi-sectoral response to the epidemics at a national and sub-national level. Therefore, SANAC is authorized to collaborate with government departments, the private health sector, other development partners, and non-governmental organizations (NGOS) to develop strategies to reach epidemic control. TACAIDS is in a unique position to conduct this work, as it has sole legal authority to provide strategic multisectorial leadership and to coordinate and strengthen efforts of all stakeholders involved in the national HIV/AIDS response. TACAIDS has 16 functions to aid in achieving their mandate. PO–RALG is in a unique position to conduct this work, as it is legally the only government agency that interprets national policies, strategies, and guidelines related to health and social welfare sector development, financing, and human resources; provides supportive supervision and mentorship to RAs and LGAs; and ensures implementation of policies and regulations by RAs and LGAs. PO– RALG has oversight and management of all dispensaries, health facilities, and regional hospitals, as well as all health care workers. VAAC is in a unique position to conduct this work, as it uniquely qualified for this funding opportunity because of their political mandate, clearly acknowledged leadership by all partners, and significant experience to continue a strong and vital coordinating role for HIV programs. Summary of the award: Recipient: Namibia Ministry of Health and Social Services (MOHSS), Rwanda Biomedical Center, South African Medical Research Council, South African National AIDS Council Trust (SANAC), Tanzania Commission for AIDS (TACAIDS), President’s Office— Regional Administration and Local Government (PO–RALG), and Vietnam Administration for HIV/AIDS Control (VAAC). Purpose of the Award: The purpose of these awards is to strengthen VerDate Sep<11>2014 16:17 Feb 06, 2024 Jkt 262001 comprehensive and integrated service delivery for prevention and implement strategies and activities that strengthen local entities, support the coordination, management, and monitoring of multisectoral implementation, foster the government’s capacity to provide comprehensive management of the HIV program, and implement a sustainable and quality-assured HIV diagnostic, testing, and health information management program in Namibia, Rwanda, South Africa, Tanzania, and Vietnam. Amount of Award: For MOHSS, the approximate year 1 funding amount will be $8,000,000 in Federal Fiscal Year (FYY) 2024 funds, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation. Amount of Award: For Rwanda Biomedical Center, the approximate year 1 funding amount will be $4,000,000 in Federal Fiscal Year (FYY) 2024 funds, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation. Amount of Award: For South African Medical Research Council, the approximate year 1 funding amount will be $(3,000,000 in Federal Fiscal Year (FYY) 2024 funds, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation. Amount of Award: For SANAC, the approximate year 1 funding amount will be $3,000,000 in Federal Fiscal Year (FYY) 2024 funds, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation. Amount of Award: For TACAIDS, the approximate year 1 funding amount will be $500,000 in Federal Fiscal Year (FYY) 2024 funds, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation. Amount of Award: For PO–RALG, the approximate year 1 funding amount will be $500,000 in Federal Fiscal Year (FYY) 2024 funds, subject to the availability of funds. Amount of Award: For VAAC, the approximate year 1 funding amount will be $6,000,000 in Federal Fiscal Year (FYY) 2024 funds, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation. Authority: These programs are authorized under Public Law 108–25 (the United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act of 2003) [22 U.S.C. 7601, et seq.] and Public Law 110–293 (the Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008), and Public Law 113–56 (PEPFAR Stewardship and Oversight Act of 2013). PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 8433 Period of Performance: The period for these awards will be September 30, 2024, through September 29, 2029. Dated: January 24, 2024. Jamie Legier, Acting Director, Office of Grants Services, Acting Chief Grants Management Officer, Centers for Disease Control and Prevention. [FR Doc. 2024–02505 Filed 2–6–24; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Notice of Award of a Sole Source Cooperative Agreement To Fund the Pan-American Health Organization (PAHO) Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice. AGENCY: The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately $8,000,000, with an expected total funding of approximately $50,000,000 over a 5-year period, to the Pan-American Health Organization (PAHO). The award will support strengthening immunization systems; ensuring polio free certification status; maintaining measles, rubella, and neonatal tetanus elimination; and prevention of other vaccine-preventable diseases (VPDs) in the Americas region. This award builds upon and continues work previously supported by PAHO through a cooperative agreement under CDC–RFA–GH–1901, ‘‘Cooperative Agreement with the Pan American Health Organization: Protecting and Strengthening Immunization Programs in the Americas.’’ DATES: The period for this award will be May 1, 2024, through April 30, 2029. FOR FURTHER INFORMATION CONTACT: Mary A. Mulholland, (Global Health Center, Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, Atlanta, GA 30333, Telephone: 404– 553–7371, Email: mmulholland@ cdc.gov. SUMMARY: The sole source award will establish a cooperative agreement that will build upon the achievements of past cooperative agreements with PAHO, while forging new collaborations to strengthen the Expanded Program on Immunization in the Americas as a SUPPLEMENTARY INFORMATION: E:\FR\FM\07FEN1.SGM 07FEN1 khammond on DSKJM1Z7X2PROD with NOTICES 8434 Federal Register / Vol. 89, No. 26 / Wednesday, February 7, 2024 / Notices whole. Supported activities will includes development of standards for national immunization programs, development of national immunization program capacity to prevent, detect and respond to VPDs, and maintain the status of polio eradication; rubella, measles, and neonatal tetanus elimination; and support the elimination of Hepatitis B. To achieve these strategies, the recipient will provide direct technical cooperation to Member States through both its regional headquarters and country offices. PAHO is in a unique position to conduct this work, as it functions as the lead specialized health agency within the inter-American system and operates as the regional office for the Americas on behalf of the World Health Organization (WHO), the UN’s specialized health agency, with headquarters in Washington DC. Through their presence in the 35 member countries in the region, PAHO promotes technical cooperation between countries and works in partnership with ministries of health and other government agencies, civil society organizations, other international agencies, universities, social security agencies, community groups, and other partners. During nearly three decades of partnership with CDC’s Global Immunization Division, PAHO has made outstanding progress towards strengthening routine immunization and surveillance systems for polio, measles, rubella, and congenital rubella syndrome; including maintaining the revolving fund for the bulk purchase of vaccines for member countries; developing a strong platform for strengthening surveillance of other VPDs; and maintaining its polio-free certification since 1994, as well as verification of regional rubella and CRS elimination since 2015 and regional measles elimination since 2016. Summary of the award: Recipient: Pan-American Health Organization (PAHO). Purpose of the Award: The purpose of this award is to support strengthening immunization systems; ensuring polio free certification status; maintaining measles, rubella, and neonatal tetanus elimination; and prevention of other VPDs in the Americas region, in alignment with the US Government endorsed Global Polio Eradication Initiative, the Immunization Agenda 2030 and CDC’s Global Immunization Strategic Framework 2021–2030. Additionally, this NOFO supports CDC’s Global Health Strategy which focuses on protecting and improving the health, safety, security, and well-being of Americans by reducing morbidity and VerDate Sep<11>2014 16:17 Feb 06, 2024 Jkt 262001 mortality worldwide; improving capabilities to prepare for and respond to infectious diseases and other emerging health threats and public health emergencies; and maximizing potential of CDC’s global programs to achieve public health impact. Amount of Award: $8,000,000 in Federal fiscal year (FFY) 2024 funds, with a total estimated $ 50,000,000 for the 5-year period of performance, subject to availability of funds. Funding amounts for years 2–5 will be set at continuation. Authority: This program is authorized under Section 307 of the PHS Act (42 U.S.C 242); section 317(k)(1) and (2) of the PHS Act (42 U.S.C. 247b(k)(1) and (2). Period of Performance: May 1, 2024, through April 30, 2029. Dated: January 24, 2024. Jamie Legier, Acting Director, Office of Grants Services, Acting Chief Grants Management Officer, Centers for Disease Control and Prevention. [FR Doc. 2024–02507 Filed 2–6–24; 8:45 am] BILLING CODE 4163–18–P information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden. Comments on the collection(s) of information must be received by the OMB desk officer by March 8, 2024. ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/ PRAMain. Find this particular information collection by selecting ‘‘Currently under 30-day Review—Open for Public Comments’’ or by using the search function. To obtain copies of a supporting statement and any related forms for the proposed collection(s) summarized in this notice, please access the CMS PRA website by copying and pasting the following web address into your web browser: https://www.cms.gov/ Regulations-and-Guidance/Legislation/ PaperworkReductionActof1995/PRAListing. DATES: FOR FURTHER INFORMATION CONTACT: DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services [Document Identifier: CMS–10448] Agency Information Collection Activities: Submission for OMB Review; Comment Request Centers for Medicare & Medicaid Services, Health and Human Services (HHS). ACTION: Notice. AGENCY: The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS’ intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (PRA), federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, and to allow a second opportunity for public comment on the notice. Interested persons are invited to send comments regarding the burden estimate or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency’s functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the SUMMARY: PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 William Parham at (410) 786–4669. Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501–3520), federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. The term ‘‘collection of information’’ is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires federal agencies to publish a 30-day notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, CMS is publishing this notice that summarizes the following proposed collection(s) of information for public comment: 1. Type of Information Collection Request: Revision of a currently approved collection; Title of Information Collection: Essential Health Benefits Benchmark Plans; Use: On March 23, 2010, the Patient Protection and Affordable Care Act (PPACA; Pub. L. 111–148) was signed into law, and on March 30, 2010, the Health Care and Education Reconciliation Act of 2010 (Pub. L. 111–152) was signed into law. SUPPLEMENTARY INFORMATION: E:\FR\FM\07FEN1.SGM 07FEN1

Agencies

[Federal Register Volume 89, Number 26 (Wednesday, February 7, 2024)]
[Notices]
[Pages 8433-8434]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-02507]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Notice of Award of a Sole Source Cooperative Agreement To Fund 
the Pan-American Health Organization (PAHO)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC), located 
within the Department of Health and Human Services (HHS), announces the 
award of approximately $8,000,000, with an expected total funding of 
approximately $50,000,000 over a 5-year period, to the Pan-American 
Health Organization (PAHO). The award will support strengthening 
immunization systems; ensuring polio free certification status; 
maintaining measles, rubella, and neonatal tetanus elimination; and 
prevention of other vaccine-preventable diseases (VPDs) in the Americas 
region. This award builds upon and continues work previously supported 
by PAHO through a cooperative agreement under CDC-RFA-GH-1901, 
``Cooperative Agreement with the Pan American Health Organization: 
Protecting and Strengthening Immunization Programs in the Americas.''

DATES: The period for this award will be May 1, 2024, through April 30, 
2029.

FOR FURTHER INFORMATION CONTACT: Mary A. Mulholland, (Global Health 
Center, Centers for Disease Control and Prevention, 1600 Clifton Rd. 
NE, Atlanta, GA 30333, Telephone: 404-553-7371, Email: 
[email protected].

SUPPLEMENTARY INFORMATION: The sole source award will establish a 
cooperative agreement that will build upon the achievements of past 
cooperative agreements with PAHO, while forging new collaborations to 
strengthen the Expanded Program on Immunization in the Americas as a

[[Page 8434]]

whole. Supported activities will includes development of standards for 
national immunization programs, development of national immunization 
program capacity to prevent, detect and respond to VPDs, and maintain 
the status of polio eradication; rubella, measles, and neonatal tetanus 
elimination; and support the elimination of Hepatitis B. To achieve 
these strategies, the recipient will provide direct technical 
cooperation to Member States through both its regional headquarters and 
country offices.
    PAHO is in a unique position to conduct this work, as it functions 
as the lead specialized health agency within the inter-American system 
and operates as the regional office for the Americas on behalf of the 
World Health Organization (WHO), the UN's specialized health agency, 
with headquarters in Washington DC. Through their presence in the 35 
member countries in the region, PAHO promotes technical cooperation 
between countries and works in partnership with ministries of health 
and other government agencies, civil society organizations, other 
international agencies, universities, social security agencies, 
community groups, and other partners. During nearly three decades of 
partnership with CDC's Global Immunization Division, PAHO has made 
outstanding progress towards strengthening routine immunization and 
surveillance systems for polio, measles, rubella, and congenital 
rubella syndrome; including maintaining the revolving fund for the bulk 
purchase of vaccines for member countries; developing a strong platform 
for strengthening surveillance of other VPDs; and maintaining its 
polio-free certification since 1994, as well as verification of 
regional rubella and CRS elimination since 2015 and regional measles 
elimination since 2016.
    Summary of the award:
    Recipient: Pan-American Health Organization (PAHO).
    Purpose of the Award: The purpose of this award is to support 
strengthening immunization systems; ensuring polio free certification 
status; maintaining measles, rubella, and neonatal tetanus elimination; 
and prevention of other VPDs in the Americas region, in alignment with 
the US Government endorsed Global Polio Eradication Initiative, the 
Immunization Agenda 2030 and CDC's Global Immunization Strategic 
Framework 2021-2030. Additionally, this NOFO supports CDC's Global 
Health Strategy which focuses on protecting and improving the health, 
safety, security, and well-being of Americans by reducing morbidity and 
mortality worldwide; improving capabilities to prepare for and respond 
to infectious diseases and other emerging health threats and public 
health emergencies; and maximizing potential of CDC's global programs 
to achieve public health impact.
    Amount of Award: $8,000,000 in Federal fiscal year (FFY) 2024 
funds, with a total estimated $ 50,000,000 for the 5-year period of 
performance, subject to availability of funds. Funding amounts for 
years 2-5 will be set at continuation.
    Authority: This program is authorized under Section 307 of the PHS 
Act (42 U.S.C 242); section 317(k)(1) and (2) of the PHS Act (42 U.S.C. 
247b(k)(1) and (2).
    Period of Performance: May 1, 2024, through April 30, 2029.

    Dated: January 24, 2024.
Jamie Legier,
Acting Director, Office of Grants Services, Acting Chief Grants 
Management Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-02507 Filed 2-6-24; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.